CDKN1A and neoplasm: Notably, saRNAs designed to target CEBPA have previously exhibited the capability to augment the expression of CEBPA along with its downstream effector, cyclin-dependent kinase inhibitor 1 (P21), inducing an antitumor response and diminishing tumor volume in murine PDAC models [17, 22].